News

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.
Both Drugs Led to Significant Weight Loss. Almost one-third of participants on Zepbound lost at least 25 percent of their body weight, compared with 16 percent for Wegovy.
Trial reveals if Zepbound or Wegovy is better for weight loss Why you should care: People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo ...
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there? Here's what to know.
Modern weight loss medications represent a breakthrough, but they are most effective when combined with the right lifestyle strategies. Here's what that looks like.
Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, ... Study directly compares Zepbound and Wegovy for weight-loss results. Show comments.
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic ...
UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 ...
MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy. The ...
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...
A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head trial of the blockbuster weight-loss medications. Participants who took ...